Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A3 | P43003 | 1/20 | 0.63 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.63 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | ACE | P12821 | 7/20 | 0.54 |
| ▸ | ALPI | P09923 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.53 |
| ▸ | XIAP | P98170 | 1/20 | 0.53 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.53 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | CPA1 | P15085 | 2/20 | 0.50 |
| ▸ | CPA3 | P15088 | 2/20 | 0.50 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.50 |
| ▸ | CPB1 | P15086 | 1/20 | 0.50 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.50 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5511480 | 1.00 | SLC1A3 (0.63) | SLC1A3SLC1A2SLC1A1CYP1A2ACE | |
| (2R,3R)-2,3-Dibenzylsuccinic Acid SCHEMBL2919214 | 0.87 | SLC1A3 (0.73) | SLC1A3SLC1A2SLC1A1CYP1A2ACE | |
| (2R,3R)-2,3-Dibenzylsuccinic Acid SCHEMBL305323 | 0.87 | SLC1A3 (0.73) | SLC1A3SLC1A2SLC1A1CYP1A2ACE | |
| (2R,3R)-2,3-Dibenzylsuccinic Acid SCHEMBL4755513 | 0.87 | SLC1A3 (0.73) | SLC1A3SLC1A2SLC1A1CYP1A2ACE | |
| (2R,3R)-2,3-Dibenzylsuccinic Acid SCHEMBL7289849 | 0.87 | SLC1A3 (0.73) | SLC1A3SLC1A2SLC1A1CYP1A2ACE | |
| SCHEMBL24252143 | 0.86 | SLC1A3 (0.61) | SLC1A3SLC1A2SLC1A1CYP1A2ACE | |
| SCHEMBL5708390 | 0.86 | SLC1A3 (0.61) | SLC1A3SLC1A2SLC1A1CYP1A2ACE | |
| SCHEMBL19647227 | 0.86 | ALPI (0.52) | SLC1A3SLC1A2SLC1A1CYP1A2ACE | |
| SCHEMBL7415792 | 0.86 | SLC1A3 (0.61) | SLC1A3SLC1A2SLC1A1CYP1A2ACE | |
| SCHEMBL12768183 | 0.86 | ALPI (0.52) | SLC1A3SLC1A2SLC1A1CYP1A2ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115873020-A | RAS inhibitors | 锐新医药公司 | 2023-03-31 | — | — | CN | disclosed |
| US-20230047816-A1 | PFKFB3 INHIBITORS AND THEIR USES | GERO PTE. LTD. (SG) | 2023-02-16 | — | — | US | disclosed |
| US-11206835-B2 | Air purification composition with antiviral and bactericidal functions | Guorun Biotechnology (Shenzhen) Co., Ltd. (CN) | 2021-12-28 | — | — | US | disclosed |
| WO-2021195183-A1 | COMPOSITIONS AND METHODS FOR INHIBITING PROTEIN EMBRYONIC ECTODERM DEVELOPMENT ACTIVITY AND TREATING DISEASE | EXO THERAPEUTICS, INC. (US) | 2021-09-30 | — | — | WO | disclosed |
| EP-3327027-B9 | CYTOTOXIC PEPTIDES AND ANTIBODY DRUG CONJUGATES THEREOF | PFIZER (US) | 2021-07-07 | — | — | EP | disclosed |
| EP-3327027-B1 | CYTOTOXIC PEPTIDES AND ANTIBODY DRUG CONJUGATES THEREOF | PFIZER (US) | 2021-01-06 | — | — | EP | disclosed |
| US-20200329717-A1 | NOVEL AIR PURIFICATION COMPOSITION WITH ANTIVIRAL AND BACTERICIDAL FUNCTIONS | Guorun Biotechnology (Shenzhen) Co., Ltd. (CN) | 2020-10-22 | — | — | US | disclosed |
| EP-3650105-A1 | NOVEL AIR PURIFICATION COMPOSITION HAVING ANTIVIRAL AND BACTERICIDAL FUNCTIONS | Wang, Jingning (CN) | 2020-05-13 | — | — | EP | disclosed |
| US-20200033314-A1 | SENSOR DYES FOR REAL-TIME SENSING OF METAL IONS IN AQUEOUS ENVIRONMENTS | ADVANCED CHEMICAL SYSTEMS, INC. | 2020-01-30 | — | — | US | disclosed |
| WO-2020015053-A1 | NOVEL AIR PURIFICATION COMPOSITION HAVING ANTIVIRAL AND BACTERICIDAL FUNCTIONS | 王婧宁 | 2020-01-23 | — | — | WO | disclosed |
| US-20130079319-A1 | CEPHEM COMPOUND HAVING PSEUDO-CATECHOL GROUP | SHIONOGI & CO., LTD. (JP) | 2013-03-28 | — | — | US | disclosed |
| US-RE43298-E1 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2012-04-03 | — | — | US | disclosed |
| WO-2012038813-A1 | BUPRENORPHINE ANALOGS | PURDUE PHARMA L.P. (US) | 2012-03-29 | — | — | WO | disclosed |
| US-20110117057-A1 | NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | SCHERING CORPORATION (US) | 2011-05-19 | — | — | US | disclosed |
| US-20100137294-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR CONTROLLING INVERTEBRATE PESTS | GENETIC TECHNOLOGIES LIMITED (AU) | 2010-06-03 | — | — | US | disclosed |
| US-20070225285-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. (US) | 2007-09-27 | — | — | US | disclosed |
| US-20070225285-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. (US) | 2007-09-27 | — | — | US | disclosed |
| US-20070219206-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. (US) | 2007-09-20 | — | — | US | disclosed |
| WO-2003062265-A2 | NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | SCHERING CORPORATION (US) | 2003-07-31 | — | — | WO | disclosed |
| EP-0698010-A1 | N-ACYL SULFAMIC ACID ESTERS (OR THIOESTERS), N-ACYL SULFONAMIDES, AND N-SULFONYL CARBAMIC ACID ESTERS (OR THIOESTERS) AS HYPERCHOLESTEROLEMIC AGENTS | WARNER-LAMBERT COMPANY (US) | 1996-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130079319-A1 | CEPHEM COMPOUND HAVING PSEUDO-CATECHOL GROUP | CENPE, CCNE2, CEP170 | SLC1A3 1131/4885SLC1A2 915/4885SLC1A1 847/4885 |
| US-20070225285-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | ALOX5, ALOX15B, ALOX15 | SLC1A3 4721/4885SLC1A2 4764/4885SLC1A1 4759/4885 |
| US-20230047816-A1 | PFKFB3 INHIBITORS AND THEIR USES | PFKFB3, PFKFB4, PFKFB1 | SLC1A3 118/4885SLC1A2 647/4885SLC1A1 265/4885 |
| US-20110117057-A1 | NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | HPN, TMPRSS15, VIP | SLC1A3 4240/4885SLC1A2 4759/4885SLC1A1 4345/4885 |
| US-20100137294-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR CONTROLLING INVERTEBRATE PESTS | PPP1R10, TASP1, PPP5C | SLC1A3 3386/4885SLC1A2 3416/4885SLC1A1 3129/4885 |
| US-20070219206-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | ALOX5, ALOX15B, ALOX15 | SLC1A3 4721/4885SLC1A2 4764/4885SLC1A1 4759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.